In a report released on May 10, Mathew Blackman from Stifel Nicolaus maintained a Hold rating on Insulet (PODD – Research Report), with a price target of $185.00. The company’s shares closed last Friday at $165.90.
Blackman covers the Healthcare sector, focusing on stocks such as Tandem Diabetes Care, Globus Medical, and Alphatec Holdings. According to TipRanks, Blackman has an average return of 15.0% and a 51.09% success rate on recommended stocks.
In addition to Stifel Nicolaus, Insulet also received a Hold from Barclays’s Matt Miksic in a report issued on May 10. However, on the same day, Jefferies reiterated a Buy rating on Insulet (NASDAQ: PODD).
The company has a one-year high of $331.65 and a one-year low of $125.82. Currently, Insulet has an average volume of 918.1K.
Based on the recent corporate insider activity of 57 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PODD in relation to earlier this year. Most recently, in February 2024, Shacey Petrovic, a Director at PODD sold 11,609.00 shares for a total of $1,891,338.28.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Insulet (PODD) Company Description:
Insulet Corp. is a medical device company. The firm engages in the development, manufacture and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.
Read More on PODD:
